The drug has shown strong results in phase 3 clinical trials, which are the basis for the new application to the FDA.

The FDA has accepted a new drug application for aficamten, a new obstructive hypertrophic cardiomyopathy drug. A goal date ...

Vitamin D receptor has antiproliferative effects in pulmonary arterial hypertension, but receptor expression is downregulated ...

Effective July 1, 2025, this agreement ensures that nearly 400,000 patients covered by IBX each year will keep receiving quality care from Penn Medicine providers. The partnership focuses on improving ...

A new nationwide study led by the Keck School of Medicine of USC aims to examine how Type 1 diabetes impacts children's brain ...

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...

Seemal Desai, M.D., FAAD, discusses how managed care organizations can improve access to advanced vitiligo treatments through ...

Two industry-sponsored studies investiaged needs of people with pulmonary hypertesion and interstitial lung disease.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...

New data suggests clinicians may be slower to recognize sepsis in people with pulmonary arterial hypertension.

Paul Fronstin, director of Health Benefits Research at EBRI, discussed ERISA and trends in employer self-insurance during a ...